Abattis Announces Board Changes

Vancouver, British Columbia--(Newsfile Corp. - April 13, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQB: ATTBF) is pleased to announce the addition of Cameron Paddock to the Board of Directors. Mr. Paddock will fill the vacancy left by the resignation of Dr. Will Panenka who is leaving the Company to concentrate on other ventures.

"We are very excited have Mr. Paddock join our Board. On behalf of the Company, I would like to thank Dr. Panenka for his contributions to the Company and wish him all the best in his future endeavours," stated Robert Abenante, President and CEO of Abattis. "We are pleased to welcome Mr. Paddock to our Board and look forward his contributions to our Company's leadership and direction," added Mr. Abenante.

Mr. Paddock currently manages a family office while serving as a director of a number of public and private companies involved in the cannabis, technology, and mining sectors. Mr Paddock has extensive experience with business development, corporate governance and mergers and acquisitions.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com.

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "intends", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: Mr. Paddock's future contributions to the Company's leadership and direction. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that Mr. Paddock will not contribute, as expected, to the Company's leadership and direction; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company's competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company's control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.